The Unstoppable Pharma Power! Eli Lilly is the Benchmark After Acquiring Orna Therapeutics!
Reading Time: 4 minutes
While the eternal rival Novo Nordisk is struggling, Eli Lilly (LLY) shows no signs of slowing down. Driven by an unprecedented weight loss boom, revenues are skyrocketing, but management wants more. With an aggressive acquisition, a clever move on the TrumpRx platform, and a billion-dollar alliance in China, the company is radically expanding its global dominance. Eli Lilly remains the most exciting growth story of 2026. Billions from the Weight Loss Boom - A Record Quarter Eli Lilly ended 2025 with a true fireworks display, posting numbers that...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
